DNA methylation in small lung adenocarcinoma with bronchioloalveolar carcinoma components

Takafumi Kubo, Hiromasa Yamamoto, Koichi Ichimura, Masaru Jida, Tatsuro Hayashi, Hiroki Otani, Kazunori Tsukuda, Yoshifumi Sano, Katsuyuki Kiura, Shinichi Toyooka

Research output: Contribution to journalArticle

20 Citations (Scopus)


We examined the methylation status in 100 specimens of lung adenocarcinomas measuring 2 cm or less and with bronchioloalveolar carcinoma (BAC) components (Noguchi types A-C) and then compared the methylation status between noninvasive tumors (Noguchi type A or B) and invasive tumors (Noguchi type C). Methylation-specific PCR was used to determine the methylation statuses of p16INK4a, RASSF1A, CDH13, RARβ, and Cyclin D2. The methylation index that was regarded as representing the degree of methylation was calculated. We also determined the mutational statuses of EGFR exons 19 and 21 using a PCR-based method. A multivariate analysis showed that the aberrant methylation of p16INK4a, RASSF1A, and CDH13 was significantly more frequent in invasive tumors than in noninvasive tumors [p16INK4a, 36.5% versus (vs.) 8.3%, P = 0.0023; RASSF1A, 46.2% vs. 14.6%, P = 0.0012; CDH13, 42.3% vs. 10.4%, P = 0.0006]. The methylation index was significantly higher in invasive tumors than in noninvasive tumors (P = 0.004). The methylation of p16INK4a was significantly more frequent in EGFR wild-type tumors than in EGFR mutant tumors (P = 0.021). Our results indicate the involvement of epigenetic alterations in the progression of adenocarcinoma with BAC components.

Original languageEnglish
Pages (from-to)328-332
Number of pages5
JournalLung Cancer
Issue number3
Publication statusPublished - Sep 1 2009



  • BAC
  • CDH13
  • Cyclin D2
  • Methylation
  • RARβ
  • p16

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this